This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC)； treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient)； treating and preventing loss of physical function due to cancer or cancer therapy； increase of physical function； and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.
